Amylin: The Second Satiety Signal That GLP-1 Drugs Never Touch
Most men who have looked into weight-loss medicine know one hormone by name. GLP-1 is on the label of every drug in the category, in every headline, and in most of the arguments about it. Almost nobody has heard of amylin, which is strange, because your pancreas has been releasing it into your bloodstream at every meal of your life. It was identified in 1987, in the same islet cells that make insulin, and then it sat on the shelf for decades while the industry chased other targets. That has changed. The compounds built around amylin, on their own and paired with a GLP-1, have produced some of the largest weight-loss figures anyone has reported in a phase 3 trial. This is an educational overview of what amylin does, why the first drug built on it went nowhere, what the recent combination trials measured, and which questions the data has not settled. It is not medical advice and not a recommendation to seek out or use any compound. None of these decisions belong anywhere except a conversation with a licensed clinician who knows your history.
A Second Hormone Leaves the Pancreas With Every Meal
Insulin does not travel alone. The same beta cells that release it also release amylin, a small peptide of 37 amino acids, in roughly fixed proportion, meal after meal. Researchers found it in 1987 while studying deposits in the pancreatic tissue of people with type 2 diabetes, which is why its formal name is islet amyloid polypeptide. For a long time that discovery context worked against it. The peptide was framed as debris rather than as a signal, something the pancreas leaves behind rather than something it sends. That reading turned out to be wrong. Amylin has its own receptors, clustered in a patch of the hindbrain called the area postrema, and it uses them to report back on the meal in progress. It slows the stomach's rate of emptying, tells the liver to hold back glucagon, and pushes the brain toward the point where eating stops. In people with type 1 diabetes, where the beta cells are gone, amylin is missing along with insulin. The system has a hole in it that insulin replacement alone never filled.
Two Signals, Two Different Jobs
It is tempting to file amylin as a second copy of GLP-1, since both are meal-related peptides that reduce food intake. The lazy version of that comparison misses what makes the pair interesting. GLP-1 comes from the gut, mostly the lower small intestine, and its influence stretches well beyond the meal itself into the hours afterward. It is the signal that dampens the background chatter about food, the thing patients describe as the volume going down. Amylin comes from the pancreas and works on a shorter clock. Its strongest effect is on satiation, the process that brings a meal to an end while you are still sitting at the table. One narrows the window you eat in. The other narrows the meal itself. They also run through different receptors in different parts of the brain, which is the technical reason a combination can add up rather than overlap. When two drugs press the same receptor, you get the effect once and pay twice. That is not the situation here.
Two Satiety Signals, Two Different Emphases
GLP-1 and amylin both tell the brain that food has arrived, but they lean on different parts of the job. Amylin acts mostly on the meal you are eating right now, cutting it short. GLP-1 reaches further into the hours between meals, where the wanting lives. The bars show where each signal puts its weight based on how the two pathways are described in the physiology literature. They are a map of emphasis, not measured potency.
- GLP-1 pathway
- Amylin pathway
The First Amylin Drug Was a Commercial Failure
Amylin already had its shot. Pramlintide reached the market in 2005 as an injectable analogue for people with diabetes, and by any commercial measure it disappointed. The weight effect was real but small, generally a few pounds. The reason had almost nothing to do with the biology and almost everything to do with the molecule. Native amylin aggregates and clears quickly, so pramlintide had to be dosed before every major meal, which meant three or more injections a day on top of insulin. Patients were also asked to lower their mealtime insulin dose at the same time to manage hypoglycemia risk. Ask someone to add three daily injections and adjust another drug for a few pounds of benefit, and most will decline. Adherence collapsed and the drug never found a wide audience. What is worth noticing is which part failed. Nobody concluded that the amylin pathway was a dead end. The chemistry was the problem, and chemistry is a solvable problem.
What Changed With Cagrilintide
The fix was the same trick that turned GLP-1 from a laboratory curiosity into a category of blockbuster drugs. Attach a fatty acid chain to the peptide so it binds reversibly to albumin in the blood, and the molecule stops being cleared in hours. Cagrilintide is a long-acting amylin analogue engineered along those lines, dosed once a week rather than before every meal. It is also less prone to the aggregation that made native amylin so difficult to formulate, and it activates both the amylin receptors and the closely related calcitonin receptors. The clinical difference is not subtle. In its own trials, cagrilintide as a single agent produced average body-weight reductions in the low double digits over about a year, which is territory that pramlintide never approached. Same pathway, same target tissue, roughly the same biology. The change was making a molecule a person would realistically keep taking.
What the Combination Trials Reported
The obvious next experiment was to pair the amylin analogue with a GLP-1 and see whether the two signals stacked. The phase 3 program did exactly that, combining cagrilintide with semaglutide 2.4 mg in a single weekly injection and running it against each agent alone and against placebo for 68 weeks. Across roughly 3,400 participants with obesity, the combination arm reported an average body-weight reduction of about 22.7 percent. The GLP-1 alone came in near 16.1 percent, the amylin analogue alone near 11.8 percent, and placebo near 2.3 percent. A companion trial in people with type 2 diabetes, a group that consistently loses less weight on these drugs, reported a smaller but still substantial figure in the low double digits. Two things are worth flagging before anyone reads too much into the headline. Trial averages describe a group, not a person, and the spread of individual results in these studies is wide. The combination also fell somewhat short of the number the sponsor had guided toward, which is a reminder of how much expectation gets priced into this field before the data arrives.
What 68 Weeks Looked Like in the Combination Trial
The headline result from the phase 3 combination program was that neither hormone alone matched what the pair did together. The amylin analogue on its own landed in the low double digits. The GLP-1 alone landed higher. Running both pushed the average past twenty percent of starting body weight. Lines trace reported average body-weight change from baseline across the trial arms. Individual results in any trial vary widely around these averages.
- Placebo
- Amylin analogue alone
- GLP-1 alone
- Both together
The Responder Rates Are the More Useful Number
Average weight loss is the figure that makes headlines and the least informative number in the report. It says nothing about who actually got there. Responder rates, the share of participants crossing a specific threshold, map much better onto what a clinician sees in practice, and this is where the combination separated itself most clearly. At the modest end, the difference between one hormone and two was narrow, because most people on a GLP-1 already clear a five percent loss. The gap widened as the threshold rose. At twenty percent of starting body weight, a level that used to sit almost exclusively in bariatric surgery territory, roughly a third of the GLP-1 group crossed it against well over half of the combination group. That pattern, small differences at the low bar and large ones at the high bar, is what you would expect if the second signal is genuinely adding something rather than reinforcing what the first already does.
The Number That Caught Clinicians' Attention
Average weight loss hides who actually got there. The more useful question is what share of people crossed a given threshold, because that is closer to what happens in a clinic. The gap between one hormone and two widens as the bar gets higher. At the twenty percent mark, roughly a third of the single-agent group crossed it against well over half on the combination. Bars show reported responder rates at each threshold.
- GLP-1 alone
- Both together
Two Gut-Brain Signals Did Not Mean Twice the Nausea
Anyone who has been on a GLP-1 knows the trade. The appetite effect arrives with a stomach that empties slowly and, for a stretch of weeks, complains about it. Since amylin also slows gastric emptying, the reasonable worry about combining them was that the side effects would compound. The trial arms did not show that. The amylin analogue on its own reported gastrointestinal complaints at a rate close to placebo. Adding it to the GLP-1 raised the gastrointestinal rate only modestly above the GLP-1 alone, and the reported events were mostly mild to moderate and clustered in the dose-escalation phase, the same pattern familiar from single-agent GLP-1 use. Discontinuation for side effects sat in a range broadly consistent with what these drugs already produce. This is a real finding, not a marketing line, and it is part of why the combination approach drew as much attention as it did. It is also not a safety guarantee. Longer follow-up in wider populations is where the durable answers about tolerability come from, and that follow-up is still accumulating.
Adding a Second Hormone Did Not Double the Nausea
The obvious worry about stacking two gut-brain signals is that stomach complaints stack with them. That is not what the trial arms showed. The amylin analogue on its own sat close to placebo, and adding it to a GLP-1 moved the gastrointestinal rate only slightly above the GLP-1 alone. Bars show the reported share of participants in each arm noting any gastrointestinal side effect, most of it mild and concentrated in the dose-escalation weeks.
The Lean-Mass Question Is Still Open
Fast weight loss takes muscle with it, and that concern applies to any drug in this class. The interesting question about amylin is whether it changes the ratio. There is a mechanistic argument that it might, because amylin analogues appear to work partly by restoring the brain's sensitivity to leptin, the hormone that reports on how much fat is in storage. A body that can read its own fat stores accurately has less reason to raid muscle for fuel, at least in theory. Some of the reported body-composition data from the combination trials has been read as pointing in that direction, with a favorable share of the loss coming from fat rather than lean tissue. Read that carefully. Body-composition measurement in weight-loss trials is done on subsets, with different methods and different definitions, and it is not the outcome these studies were designed to answer. The honest summary is that the signal is interesting and the evidence is preliminary. Nothing about it changes the two things that reliably defend muscle during weight loss, which remain resistance training and adequate protein.
What Is Actually in the Pipeline
Amylin has gone from an ignored target to one of the most crowded areas in metabolic drug development, and the shape of that pipeline says something about where the field thinks it is headed. Cagrilintide paired with semaglutide is the furthest along, under regulatory review at the time of writing rather than approved, which is a distinction worth keeping straight when reading enthusiastic coverage. Behind it sits amycretin, a single molecule engineered to hit both the GLP-1 and amylin receptors at once instead of combining two peptides, with early-phase results that landed in a similar range to the two-drug combination. Other companies are developing amylin analogues as standalone therapies, on the argument that a compound with a gentler side-effect profile and no GLP-1 attached might suit people who cannot tolerate the current drugs. What all of these share is the abandonment of a single-receptor model. The first generation asked one question of the body. The current generation asks two or three, on the reasoning that appetite was never governed by one hormone in the first place.
Twenty Years of Amylin Drugs, Compressed
The first amylin drug reached pharmacies in 2005 and barely moved weight. What changed was not the biology but the chemistry that let the molecule survive a full week in the body. The newer analogues, alone and paired with a GLP-1, sit in a different range entirely. Bars show average body-weight reduction reported for each compound in its own trials, which used different designs and durations and are not head-to-head comparisons.
What This Means If You Are Watching From the Sidelines
For most people reading about this, the practical takeaway is not a compound to go find. It is a correction to a mental model. The popular story about weight-loss medicine has been a story about one hormone, and that story was always incomplete. Appetite is regulated by a set of overlapping signals, and the field is now working through the ones that were skipped. Amylin is the clearest example so far of what happens when a neglected pathway finally gets a molecule good enough to test properly. It is also a useful check on the reflex to treat every new number as an upgrade. A larger average weight loss is not automatically the better clinical choice for a given person, and none of these compounds have the long-term safety record that the older ones are slowly building. If any of this is relevant to your situation, the conversation that matters is with a physician who can weigh your history, your labs, and what is actually available and approved, rather than what is promising in a press release. Everything here is educational background for that conversation, not a substitute for it.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
What Is the Difference Between Peptides and Copper Peptides? A Copper Peptide Is a Peptide Holding a Metal Ion, and the Skin Evidence Splits Along That Line
What is the difference between peptides and copper peptides? A copper peptide is a peptide bound to copper. How GHK-Cu differs and what skin trials show.
Tribulus Is Sold as a Testosterone Booster. Eight of Ten Trials in Men Found No Change in Male Hormones, and the Erection Benefit It Does Show Arrives Without a Testosterone Rise.
Does tribulus raise testosterone? Eight of ten trials in men found no change. A 180-man trial did show better erections. What the research found, plus safety.
Three Beers a Night for Three Weeks Cut Testosterone by About 7 Percent. The Bigger Cost to Men Who Train Shows Up in the Muscle.
Does alcohol lower testosterone? In a diet-controlled trial, about 40 grams of alcohol a day for three weeks lowered testosterone in middle-aged men by 6.8 percent. Heavy drinking lowers it far more, and alcohol after training cut muscle protein synthesis by 24 to 37 percent. An educational review of the dose, the timing and what a month off actually changes.